O'Connor Mary I, Blau Brittany E
Director, Center for Musculoskeletal Care, Yale University School of Medicine, and Yale New Haven Health, New Haven, CT, and Professor of Orthopaedics and Rehabilitation, Yale School of Medicine.
Baker Tilly, New York, NY, during this study.
Am Health Drug Benefits. 2019 Apr;12(2):66-73.
The amount of total knee arthroplasty (TKA) procedures performed in the United States has been increasing steadily and is projected to reach 3 million procedures annually by 2030 in patients aged ≥65 years. A rise in TKA procedures will increase spending on osteoarthritis treatments, which is currently the second highest category of spending for Medicare patients. Because TKA procedures account for a substantial amount of total osteoarthritis spending, payers and providers are examining methods to reduce spending on the procedure while improving clinical outcomes. Customized individually made implants have been shown to improve clinical outcomes, such as physical function and limb alignment, compared with off-the-shelf implants; however, the economic impact of customized implants has yet to be established.
To analyze TKA episode expenditures among Medicare fee-for-service (FFS) members who received a customized or an off-the-shelf implant.
Members undergoing a TKA procedure using the customized implant technology were identified in the Medicare FFS database and were propensity matched (1:5) to a cohort of members who received off-the-shelf implants. Reimbursement for the initial procedure (ie, customized and off-the-shelf procedure), a preoperative computed tomography scan, and 12-month postoperative healthcare utilization were analyzed. The overall episode expenditures were used to construct a budget impact model to calculate the per-member per-month (PMPM) spending for Medicare FFS beneficiaries.
The average total episode spending was significantly lower among the customized implant cohort ($18,585) compared with the off-the-shelf implant cohort ($20,280; a $1695 difference; <.0001). This savings resulted in $0.08 PMPM savings for the Medicare FFS program when a portion (10%) of eligible members received the customized implant technology. A sensitivity analysis, which varied with the customized implant market penetration and the percent of customized implant-eligible procedures, indicated that the savings could be as great as $0.28 PMPM.
The results of this analysis demonstrate that the use of customized implants in TKA procedures can achieve substantial savings versus off-the-shelf procedures for the Medicare FFS program, and this savings is primarily driven by a lower average initial procedure cost and lower postoperative spendings for inpatient services and skilled-nursing facility costs.
在美国,全膝关节置换术(TKA)的手术量一直在稳步增长,预计到2030年,65岁及以上患者每年的手术量将达到300万例。TKA手术量的增加将导致骨关节炎治疗费用的增加,目前骨关节炎治疗费用是医疗保险患者支出的第二大类别。由于TKA手术占骨关节炎总支出的很大一部分,支付方和医疗服务提供者正在研究在改善临床结果的同时降低该手术费用的方法。与现成的植入物相比,定制的个性化植入物已被证明能改善临床结果,如身体功能和肢体对线;然而,定制植入物的经济影响尚未确定。
分析接受定制或现成植入物的医疗保险按服务收费(FFS)成员的TKA治疗期间支出。
在医疗保险FFS数据库中识别接受定制植入技术进行TKA手术的成员,并按倾向得分匹配(1:5)到一组接受现成植入物的成员。分析初次手术(即定制和现成手术)、术前计算机断层扫描以及术后12个月医疗保健利用情况的报销情况。总体治疗期间支出用于构建预算影响模型,以计算医疗保险FFS受益人的每月人均支出(PMPM)。
定制植入物组的平均总治疗期间支出(18,585美元)显著低于现成植入物组(20,280美元;相差1695美元;P <.0001)。当一部分(10%)符合条件的成员接受定制植入技术时,这一节省为医疗保险FFS计划带来了每月人均0.08美元的节省。一项敏感性分析,根据定制植入物的市场渗透率和符合定制植入物条件的手术百分比而变化,表明节省金额可能高达每月人均0.28美元。
该分析结果表明,对于医疗保险FFS计划,在TKA手术中使用定制植入物与使用现成植入物相比可实现大幅节省,这种节省主要是由较低的平均初次手术成本以及较低的住院服务和熟练护理设施成本的术后支出所驱动。